1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Viral Conjunctivitis Pipeline Drugs Market: (FST-100 and APD-209): Industry Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023

Viral Conjunctivitis Pipeline Drugs Market: (FST-100 and APD-209): Industry Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023

  • June 2016
  • 70 pages
  • ID: 4002254
  • Format: PDF
  • By Transparency Market Research

Summary

Table of Contents

This report analyzes the current and future prospects of the viral conjunctivitis pipeline drugs market across major countries. Viral conjunctivitis is a highly contagious disease; however, not a single drug has been approved by the U.S. FDA to treat it. Hence, demand for these drugs for viral conjunctivitis is likely to increase after their expected launch.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides estimated market size in terms of US$ Mn for each drug for the period from expected launch to 2023, considering the macro and micro environmental factors. Growth rates for each drug within the market have been determined after a thorough analysis of current scenario, demographics, epidemiological study, future trends, competition with other pipeline drugs, and regulatory requirements.

The market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on the drug and geographic analysis. Based on pipeline drug, the market has been segmented into FST-100 and APD-209. Market size estimations involved in-depth study of both the drugs and product information. Additionally, market related factors such as product innovation, number of viral conjunctivitis patients in various countries, and expected launch date were taken into consideration while estimating the market size. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from expected launch to 2023.

Based on geography, the market has been analyzed for major countries: the U.S., the U.K., Germany, Australia, Japan, and Brazil. The market forecast for each of these countries has been provided for the period from expected launch in the country to 2023, along with their respective CAGRs for the forecast period from expected launch to 2023. The countries are selected based on ongoing clinical trial for FST-100 and APD-209.

A detailed qualitative analysis of factors responsible for driving and restraining the market and opportunities have been provided in the market overview section. This section of the report also provides epidemiological data and patent analysis of pipeline drugs, with a thorough analysis of the overall competitive scenario in the viral conjunctivitis pipeline drugs market.

A list of recommendations has been provided for new entrants to assist them in taking strategic initiatives to establish a strong presence in the market. The report also profiles major players in the market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The viral conjunctivitis pipeline drugs market is highly consolidated. Major companies profiled in this market report are Adenovir Pharma AB, Allergan plc, NanoViricides, Inc., Shire plc, NovaBay Pharmaceuticals, Inc., Novartis AG, Panoptes Pharma GES.M.B.H., and NicOx S.A.

The viral conjunctivitis pipeline drugs market has been segmented as follows:

Viral Conjunctivitis Pipeline Drugs Market, by Drug
FST-100
APD-209

Viral Conjunctivitis Pipeline Drugs Market, by Country
U.S.
U.K.
Germany
Australia
Japan
Brazil

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($5795)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Ragweed Pollen Allergy - Pipeline Review, H1 2020

  • $ 2000
  • February 2020
  • 35 pages

Ragweed Pollen Allergy - Pipeline Review, H1 2020SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Ragweed Pollen Allergy - Pipeline Review, H1 2020, provides an overview of the Ragweed ...


ref:plp2016

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on